How I treat the antiphospholipid syndrome

被引：48

作者：

Giannakopoulos, Bill ^{[1
,2
]}

Krilis, Steven A. ^{[1
,2
]}

机构：

[1] St George Hosp, Dept Immunol Allergy & Infect Dis, Kogarah, NSW, Australia

[2] Univ New S Wales, Dept Med, Kogarah, NSW, Australia

来源：

BLOOD | 2009年 / 114卷 / 10期

关键词：

LOW-MOLECULAR-WEIGHT; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RECURRENT PREGNANCY LOSS; UNPROVOKED VENOUS THROMBOEMBOLISM; INTERNATIONAL CONSENSUS STATEMENT; INTENSITY WARFARIN THERAPY; ARTERIAL ORIGIN ESPRIT; DEEP-VEIN-THROMBOSIS; BONE-DENSITY CHANGES; LOW-DOSE ASPIRIN;

D O I：

10.1182/blood-2009-05-220756

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This article discusses how we approach medical decision making in the treatment of the various facets of the antiphospholipid syndrome (APS), including secondary prophylaxis in the setting of venous and arterial thrombosis, as well as treatment for the prevention of recurrent miscarriages and fetal death. The role of primary thromboprophylaxis is also discussed in depth. Great emphasis is given to incorporating the most up-to-date and relevant evidence base both from the APS literature, and from large, recent, randomized controlled trials (RCTs) of primary and secondary thrombotic prophylaxis in the general population setting (ie, the population that has not been specifically investigated for APS). (Blood. 2009; 114: 2020-2030)

引用

收藏

页码：2020 / 2030

页数：11

相关论文

共 122 条

[31]

Espinola RG, 2002, THROMB HAEMOSTASIS, V87, P518

[32]

European Atrial Fibrillation Trial, 1993, LANCET, V342, P1255

[33] Antiphospholipid syndrome in pregnancy: A randomized, controlled trial of treatment [J].

Farquharson, RG ;

Quenby, S ;

Greaves, M .

OBSTETRICS AND GYNECOLOGY, 2002, 100 (03) :408-413

[34] Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells [J].

Ferrara, DE ;

Swerlick, R ;

Casper, K ;

Meroni, PL ;

Vega-Ostertag, ME ;

Harris, EN ;

Pierangeli, SS .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (09) :1558-1563

[35] Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model [J].

Ferrara, DE ;

Liu, XW ;

Espinola, RG ;

Meroni, PL ;

Abukhalaf, I ;

Harris, EN ;

Pierangeli, SS .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3272-3279

[36] Systemic lupus erythematosus in three ethnic groups -: XVI.: Association of hydroxychloroquine use with reduced risk of damage accrual [J].

Fessler, BJ ;

Alarcón, GS ;

McGwin, G ;

Roseman, J ;

Bastian, HM ;

Friedman, AW ;

Baethge, BA ;

Vilá, L ;

Reveille, JD .

ARTHRITIS AND RHEUMATISM, 2005, 52 (05) :1473-1480

[37] A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome(WAPS) [J].

Finazzi, G ;

Marchioli, R ;

Brancaccio, V ;

Schinco, P ;

Wisloff, F ;

Musial, J ;

Baudo, F ;

Berrettini, M ;

Testa, S ;

D'Angelo, A ;

Tognoni, G ;

Barbui, T .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) :848-853

[38] Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention? No [J].

Fisher, Marc .

STROKE, 2009, 40 (05) :1944-1945

[39] Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials [J].

Flaker, Greg C. ;

Gruber, Michael ;

Connolly, Stuart J. ;

Goldman, Steven ;

Chaparro, Sandra ;

Vahanian, Alec ;

Halinen, Matti O. ;

Horrow, Jay ;

Halperin, Jonathan L. .

AMERICAN HEART JOURNAL, 2006, 152 (05) :967-973

[40]

Franke CL, 1997, ANN NEUROL, V42, P857

← 1 2 3 4 5 6 7 8 9 10 →